Literature DB >> 7588832

Three-year study of antibody to Borrelia burgdorferi in southern Spain.

J Gutierrez1, M C Maroto, A De la Higuera, M Guerrero, E Padilla, G Piédrola.   

Abstract

The prevalence of anti-Borrelia burgdorferi antibodies was studied in Granada, Spain, between January 1991 and November 1993 in 354 patients with suspected Lyme disease (group 1); in 50 patients either with syphilis (n = 32) or without syphilis but with a positive Rapid Plasma Reagin test (n = 18) (group 2); and in 150 healthy subjects (group 3). In addition, intrathecal antibody production was evaluated by EIA in CSF samples obtained from 117 patients in group 1. Anti-Borrelia burgdorferi antibodies were detected by EIA in 58 patients (16.4%) in group 1, 29 (8.2%) of whom were positive by Western blot. Intrathecal antibody production was detected in one patient. In group 2, 8 (16%) patients had a positive EIA result, but none of these was confirmed by Western blot. western blot was negative for all subjects in group 3. The results of this study indicate that anti-Borrelia burgdorferi antibodies are not uncommon in our area, although Lyme disease is rare.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588832     DOI: 10.1007/BF02113437

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  [Acute meningitis caused by reactivation of the varicella-zoster virus without cutaneous lesions. Contribution to the serologic diagnosis].

Authors:  M Guerrero; J Gutiérrez; M C Maroto; R González Maldonado
Journal:  Med Clin (Barc)       Date:  1992-11-07       Impact factor: 1.725

2.  False positive serologic tests for Lyme disease after varicella infection.

Authors:  H M Feder; M A Gerber; S W Luger; R W Ryan
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

3.  Atypical bilateral symmetric erosive chronic polyarthritis in the course of Lyme disease.

Authors:  J Gutiérrez; M Palermo; M C Maroto; M Abellan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

4.  The Borrelia burgdorferi flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene.

Authors:  R Wallich; S E Moter; M M Simon; K Ebnet; A Heiberger; M D Kramer
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  Comparison of seven commercial kits for detection of antibodies to Borrelia burgdorferi.

Authors:  J L Schmitz; C S Powell; J D Folds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

6.  Lyme disease--United States, 1980.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1981-10-09       Impact factor: 17.586

7.  [Clinical value of antibody titers to Borrelia burgdorferi and titer course in neurologic disease pictures].

Authors:  E Mauch; P Vogel; H H Kornhuber; A Hähnel
Journal:  Nervenarzt       Date:  1990-02       Impact factor: 1.214

8.  Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis.

Authors:  M Karlsson; I Möllegård; G Stiernstedt; B Wretlind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

9.  Experience at a referral center for patients with suspected Lyme disease in an area of nonendemicity: first 65 patients.

Authors:  D R Burdge; D P O'Hanlon
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

10.  Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein.

Authors:  L H Sigal
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

View more
  1 in total

1.  Screening of Forestry Workers in Guadalajara Province (Spain) for Antibodies to Lymphocytic Choriomeningitis Virus, Hantavirus, Rickettsia spp. and Borrelia burgdorferi.

Authors:  Lourdes Lledó; Consuelo Giménez-Pardo; María Isabel Gegúndez
Journal:  Int J Environ Res Public Health       Date:  2019-11-15       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.